Steen Lomborg Andersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Steen Lomborg Andersen has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Ram Benny Dessau
Department of Clinical Microbiology, Zealand University Hospital, Køge, Denmark
2 shared publications - Thøger Gorm Jensen
Department of Clinical Microbiology, and Research Unit of Clinical Microbiology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
2 shared publications Agnieszka Barbara Olsén
Department of Clinical Microbiology, Herlev and Gentofte Hospital – University Hospital, Herlev, Denmark
1 shared publicationAndreas Kristian Pedersen
Department of Clinical Research, University Hospital of Southern Denmark, Aabenraa, Denmark
1 shared publication- Annette Skovby
Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
1 shared publication Astrid Rasmussen
Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark
1 shared publication
Latest Publications
- 12 November 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (3) , 667-678
Predictors of 30-day readmission in patients with bloodstream infection: a population-based cohort study
Summary Purpose To identify predictors of hospital readmissions within 30 days after discharge following a bloodstream infection (BSI). Methods Population-based study of 30,843 patients surviving after their first BSI episode, 2007–2016. Using multivariate competing risk regression analyses, we estimated subhazard ratios (sHRs) and 95% confidence intervals (CIs) for all-cause, infection-related, and unplanned readmissions. Predictors included sex, age, comorbidities, causative microorganisms, length of stay (LOS), and prior hospital admissions. Results Within 30 days of discharge, 9655 patients (31.3%) were readmitted of which 3333 (34.5%) were infection-related and 7725 (80.0%) unplanned. Higher risks of all-cause readmissions were observed for males (sHR [95% CI]: 1.07 [1.03–1.12]), those aged 0–15 years (1.41 [1.26–1.58]), and patients with several comorbidities, especially malignancies and liver diseases (sHR 1.26–2.09). BSIs caused by most microorganisms other than Escherichia coli also predicted an increased readmission risk (sHR 1.11–1.39). LOS in the first, third, and fourth quartiles also predicted a higher readmission risk (sHR 1.26, 1.14, and 1.25, respectively). Patients with prior hospitalization also had a higher readmission risk, within 31–365 (sHR 1.22 [1.16–1.28]) and 1–30 days (1.70 [1.61–1.79]). Results were similar for unplanned readmissions. For infection-related readmissions, only LOS in the first quartile (1–5 days) was associated with a higher readmission risk (1.67 [1.52–1.85]). Over the study period, the median LOS decreased, whereas readmission rates increased. Conclusion Nearly one-third of patients discharged alive after a BSI were readmitted within 30 days. Further studies are needed to determine whether some of these readmissions may be avoidable.
- 12 November 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (3) , 667-678
Predictors of 30-day readmission in patients with bloodstream infection: a population-based cohort study
Summary Purpose To identify predictors of hospital readmissions within 30 days after discharge following a bloodstream infection (BSI). Methods Population-based study of 30,843 patients surviving after their first BSI episode, 2007–2016. Using multivariate competing risk regression analyses, we estimated subhazard ratios (sHRs) and 95% confidence intervals (CIs) for all-cause, infection-related, and unplanned readmissions. Predictors included sex, age, comorbidities, causative microorganisms, length of stay (LOS), and prior hospital admissions. Results Within 30 days of discharge, 9655 patients (31.3%) were readmitted of which 3333 (34.5%) were infection-related and 7725 (80.0%) unplanned. Higher risks of all-cause readmissions were observed for males (sHR [95% CI]: 1.07 [1.03–1.12]), those aged 0–15 years (1.41 [1.26–1.58]), and patients with several comorbidities, especially malignancies and liver diseases (sHR 1.26–2.09). BSIs caused by most microorganisms other than Escherichia coli also predicted an increased readmission risk (sHR 1.11–1.39). LOS in the first, third, and fourth quartiles also predicted a higher readmission risk (sHR 1.26, 1.14, and 1.25, respectively). Patients with prior hospitalization also had a higher readmission risk, within 31–365 (sHR 1.22 [1.16–1.28]) and 1–30 days (1.70 [1.61–1.79]). Results were similar for unplanned readmissions. For infection-related readmissions, only LOS in the first quartile (1–5 days) was associated with a higher readmission risk (1.67 [1.52–1.85]). Over the study period, the median LOS decreased, whereas readmission rates increased. Conclusion Nearly one-third of patients discharged alive after a BSI were readmitted within 30 days. Further studies are needed to determine whether some of these readmissions may be avoidable.
- Open Access
- 28 November 2023
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 20 (11) , e1004314
Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: A multicentre randomised controlled trial
Background: Rapid and accurate detection of pathogens is needed in community-acquired pneumonia (CAP) to enable appropriate antibiotics and to slow the development of antibiotic resistance. We aimed to compare the effect of point-of-care (POC) polymerase chain reaction (PCR) detection of respiratory pathogens added to standard care with standard care only (SCO) on antibiotic prescriptions after acute hospital admission. Methods and findings: We performed a superiority, parallel-group, open-label, multicentre, randomised controlled trial (RCT) in 3 Danish medical emergency departments (EDs) from March 2021 to February 2022. Adults acutely admitted with suspected CAP during the daytime on weekdays were included and randomly assigned (1:1) to POC-PCR (The Biofire FilmArray Pneumonia Panel plus added to standard care) or SCO (routine culture and, if requested by the attending physician, target-specific PCR) analysis of respiratory samples. We randomly assigned 294 patients with successfully collected samples (tracheal secretion 78.4% or expectorated sputum 21.6%) to POC-PCR (n = 148, 50.4%) or SCO (146, 49.6%). Patients and investigators owning the data were blinded to the allocation and test results. Outcome adjudicators and clinical staff at the ED were not blinded to allocation and test results but were together with the statistician, blinded to data management and analysis. Laboratory staff performing standard care analyses was blinded to allocation. The study coordinator was not blinded. Intention-to-treat and per protocol analysis were performed using logistic regression with Huber–White clustered standard errors for the prescription of antibiotic treatment. Loss to follow-up comprises 3 patients in the POC-PCR (2%) and none in the SCO group. Intention-to-treat analysis showed no difference in the primary outcome of prescriptions of no or narrow-spectrum antibiotics at 4 h after admission for the POC-PCR (n = 91, 62.8%) odds ratio (OR) 1.13; (95% confidence interval (CI) [0.96, 1.34] p = 0.134) and SCO (n = 87, 59.6%). Secondary outcomes showed that prescriptions were significantly more targeted at 4-h OR 5.68; (95% CI [2.49, 12.94] p < 0.001) and 48-h OR 4.20; (95% CI [1.87, 9.40] p < 0.001) and more adequate at 48-h OR 2.11; (95% CI [1.23, 3.61] p = 0.006) and on day 5 in the POC-PCR group OR 1.40; (95% CI [1.18, 1.66] p < 0.001). There was no difference between the groups in relation to intensive care unit (ICU) admissions OR 0.54; (95% CI [0.10, 2.91] p = 0.475), readmission within 30 days OR 0.90; (95% CI [0.43, 1.86] p = 0.787), length of stay (LOS) IRR 0.82; (95% CI [0.63, 1.07] p = 0.164), 30 days mortality OR 1.24; (95% CI [0.32, 4.82] p = 0.749), and in-hospital mortality OR 0.98; (95% CI [0.19, 5.06] p = 0.986). Conclusions: In a setting with an already restrictive use of antibiotics, adding POC-PCR to the diagnostic setup did not increase the number of patients treated with narrow-spectrum or without antibiotics. POC-PCR may result in a more targeted and adequate use of antibiotics. A significant study limitation was the concurrent Coronavirus Disease 2019 (COVID-19) pandemic resulting in an unusually low transmission of respiratory virus. Trial registration: ClinicalTrials.gov (NCT04651712).
- 28 November 2023
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 20 (11) , e1004314
Open AccessEvaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: A multicentre randomised controlled trial
Background: Rapid and accurate detection of pathogens is needed in community-acquired pneumonia (CAP) to enable appropriate antibiotics and to slow the development of antibiotic resistance. We aimed to compare the effect of point-of-care (POC) polymerase chain reaction (PCR) detection of respiratory pathogens added to standard care with standard care only (SCO) on antibiotic prescriptions after acute hospital admission. Methods and findings: We performed a superiority, parallel-group, open-label, multicentre, randomised controlled trial (RCT) in 3 Danish medical emergency departments (EDs) from March 2021 to February 2022. Adults acutely admitted with suspected CAP during the daytime on weekdays were included and randomly assigned (1:1) to POC-PCR (The Biofire FilmArray Pneumonia Panel plus added to standard care) or SCO (routine culture and, if requested by the attending physician, target-specific PCR) analysis of respiratory samples. We randomly assigned 294 patients with successfully collected samples (tracheal secretion 78.4% or expectorated sputum 21.6%) to POC-PCR (n = 148, 50.4%) or SCO (146, 49.6%). Patients and investigators owning the data were blinded to the allocation and test results. Outcome adjudicators and clinical staff at the ED were not blinded to allocation and test results but were together with the statistician, blinded to data management and analysis. Laboratory staff performing standard care analyses was blinded to allocation. The study coordinator was not blinded. Intention-to-treat and per protocol analysis were performed using logistic regression with Huber–White clustered standard errors for the prescription of antibiotic treatment. Loss to follow-up comprises 3 patients in the POC-PCR (2%) and none in the SCO group. Intention-to-treat analysis showed no difference in the primary outcome of prescriptions of no or narrow-spectrum antibiotics at 4 h after admission for the POC-PCR (n = 91, 62.8%) odds ratio (OR) 1.13; (95% confidence interval (CI) [0.96, 1.34] p = 0.134) and SCO (n = 87, 59.6%). Secondary outcomes showed that prescriptions were significantly more targeted at 4-h OR 5.68; (95% CI [2.49, 12.94] p < 0.001) and 48-h OR 4.20; (95% CI [1.87, 9.40] p < 0.001) and more adequate at 48-h OR 2.11; (95% CI [1.23, 3.61] p = 0.006) and on day 5 in the POC-PCR group OR 1.40; (95% CI [1.18, 1.66] p < 0.001). There was no difference between the groups in relation to intensive care unit (ICU) admissions OR 0.54; (95% CI [0.10, 2.91] p = 0.475), readmission within 30 days OR 0.90; (95% CI [0.43, 1.86] p = 0.787), length of stay (LOS) IRR 0.82; (95% CI [0.63, 1.07] p = 0.164), 30 days mortality OR 1.24; (95% CI [0.32, 4.82] p = 0.749), and in-hospital mortality OR 0.98; (95% CI [0.19, 5.06] p = 0.986). Conclusions: In a setting with an already restrictive use of antibiotics, adding POC-PCR to the diagnostic setup did not increase the number of patients treated with narrow-spectrum or without antibiotics. POC-PCR may result in a more targeted and adequate use of antibiotics. A significant study limitation was the concurrent Coronavirus Disease 2019 (COVID-19) pandemic resulting in an unusually low transmission of respiratory virus. Trial registration: ClinicalTrials.gov (NCT04651712).
- Top Cited PapersOpen Access
- 29 June 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (26) , 2300291
Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023
A highly virulent sub-lineage of the Streptococcus pyogenes M1 clone has been rapidly expanding throughout Denmark since late 2022 and now accounts for 30% of the new invasive group A streptococcal infections. We aimed to investigate whether a shift in variant composition can account for the high incidence rates observed over winter 2022/23, or if these are better explained by the impact of COVID-19-related restrictions on population immunity and carriage of group A Streptococcus.
- 29 June 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (26) , 2300291
Top Cited PapersOpen AccessIncrease in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023
A highly virulent sub-lineage of the Streptococcus pyogenes M1 clone has been rapidly expanding throughout Denmark since late 2022 and now accounts for 30% of the new invasive group A streptococcal infections. We aimed to investigate whether a shift in variant composition can account for the high incidence rates observed over winter 2022/23, or if these are better explained by the impact of COVID-19-related restrictions on population immunity and carriage of group A Streptococcus.